Author: Bao, Hejing; Li, Gang; Fang, Yinhua; Lai, Qin; Bao, Hehong; Zheng, Yu; Hu, Yanjun
Title: Immunosuppression and cardiovascular dysfunction in patients with severe versus mild coronavirus disease 2019: a case series Cord-id: ucwl1s7k Document date: 2020_10_1
ID: ucwl1s7k
Snippet: OBJECTIVES: As coronavirus disease 2019 (COVIDâ€19) continues to spread globally, we aimed to describe and compare changes in the immune and cardiovascular systems of patients with mild versus severe COVIDâ€19 at different time points during the course of disease. METHODS: One hundred and one patients diagnosed with COVIDâ€19 who underwent serial peripheral blood collection and chest computed tomography (CT) imaging were enrolled in this study and grouped by the severity of their illness. Cha
Document: OBJECTIVES: As coronavirus disease 2019 (COVIDâ€19) continues to spread globally, we aimed to describe and compare changes in the immune and cardiovascular systems of patients with mild versus severe COVIDâ€19 at different time points during the course of disease. METHODS: One hundred and one patients diagnosed with COVIDâ€19 who underwent serial peripheral blood collection and chest computed tomography (CT) imaging were enrolled in this study and grouped by the severity of their illness. Changes in the immune and cardiovascular systems were analysed and compared between groups. RESULTS: The study included 43 women and 58 men, with a median age of 45 years (interquartile range [IQR], 16–71). We identified spleen shrinkage in 27.7% of study patients. Ratios of spleen volume to patient (skin) volume were compared, with evidence that severe patients had more splenic shrinkage than mild patients. Lymphopenia was observed in 65.3% of patients, and 27.3% of patients had persistently low levels of lymphocytes after discharge. Tachycardia occurred mainly during the first 2 days of hospitalisation, with increases in creatine kinase–myocardial band levels in 10 (9.9%) patients and arrhythmias in 16 (15.8%) patients. CONCLUSIONS: In addition to pulmonary manifestations, our study demonstrated that other organ systems can also be affected during COVIDâ€19 infection, with evidence of immunosuppression and cardiovascular dysfunction, which may contribute to increased mortality rates in critically ill COVIDâ€19 patients.
Search related documents:
Co phrase search for related documents- abbvie kaletra and lopinavir ritonavir: 1, 2, 3
- acc cardiology american college and admission day: 1
- acc cardiology american college and lopinavir ritonavir: 1
- acid testing and admission day: 1, 2, 3, 4
- acid testing and lopinavir ritonavir: 1, 2, 3, 4
- acid testing and low incidence: 1, 2
- acid testing and lung expression: 1
- acute ards and administration reduce: 1, 2, 3, 4
- acute ards and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards and low incidence: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and administration reduce: 1, 2, 3, 4
- acute ards respiratory distress syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute ards respiratory distress syndrome and low incidence: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome develop and admission day: 1
- acute ards respiratory distress syndrome develop and lopinavir ritonavir: 1
- administration reduce and lopinavir ritonavir: 1, 2
- admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Co phrase search for related documents, hyperlinks ordered by date